These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15145972)

  • 1. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline.
    Spénard J; Aumais C; Massicotte J; Tremblay C; Lefebvre M
    J Clin Pharmacol; 2004 Jun; 44(6):640-5. PubMed ID: 15145972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication.
    Spénard J; Aumais C; Massicotte J; Brunet JS; Tremblay C; Grace M; Lefebvre M
    Br J Clin Pharmacol; 2005 Oct; 60(4):374-7. PubMed ID: 16187969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori.
    Graham DY; Opekun AR; Belson G; El-Zimaity HM; Carlson MR
    Aliment Pharmacol Ther; 2005 Jan; 21(2):165-8. PubMed ID: 15679766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
    Altintaş E; Ulu O; Sezgin O; Aydin O; Camdeviren H
    Turk J Gastroenterol; 2004 Jun; 15(2):90-3. PubMed ID: 15334317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pylera for the eradication of Helicobacter pylori infection.
    Saleem A; Qasim A; O'Connor HJ; O'Morain CA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):793-9. PubMed ID: 19735221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pylera plus omeprazole: quadruple treatment for Helicobacter pylori.
    Baker DE
    Rev Gastroenterol Disord; 2008; 8(1):33-41. PubMed ID: 18477968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection.
    Navarro-Jarabo JM; Fernández N; Sousa FL; Cabrera E; Castro M; Ramírez LM; Rivera R; Ubiña E; Vera F; Méndez I; Rivas-Ruiz F; Moreno JL; Perea-Milla E
    BMC Gastroenterol; 2007 Jul; 7():31. PubMed ID: 17651479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
    Marko D; Calvet X; Ducons J; Guardiola J; Tito L; Bory F;
    Helicobacter; 2005 Feb; 10(1):22-32. PubMed ID: 15691312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects.
    Henney HR; Fitzpatrick A; Stewart J; Runyan JD
    Clin Ther; 2008 Dec; 30(12):2263-71. PubMed ID: 19167586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication rate of Helicobacter pylori in dyspeptic patients.
    Amini M; Khedmat H; Yari F
    Med Sci Monit; 2005 Apr; 11(4):CR193-5. PubMed ID: 15795700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure.
    Gisbert JP; Fuentes J; Carpio D; Tito L; Guardiola J; Tomas A; Olivares D; Calvet X
    Aliment Pharmacol Ther; 2005 May; 21(10):1249-53. PubMed ID: 15882246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers.
    Boonleang J; Panrat K; Tantana C; Krittathanmakul S; Jintapakorn W
    Clin Ther; 2007 Apr; 29(4):703-10. PubMed ID: 17617293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers.
    Krishna G; Kisicki JC; Olsen S; Grasela DM; Wang Z
    J Clin Pharmacol; 2007 May; 47(5):628-32. PubMed ID: 17395892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New ultrashort scheme for helicobacter pylori infection eradication using tetracyline, furazolidone and colloidal bismuth subcitrate in dyspeptic patients with or without peptic ulceration in the National Hospital Cayetano Heredia].
    Araujo Castillo R; Pinto Valdivia JL; Ramírez D; Cok García J; Bussalleu Rivera A
    Rev Gastroenterol Peru; 2005; 25(1):23-41. PubMed ID: 15818420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of metronidazole, tetracycline and bismuth in healthy volunteers after oral administration of compound tablets containing a combination of metronidazole, tetracycline hydrochloride and bismuth oxide.
    Wu Y; Ding L; Huang NY; Wen AD; Liu B; Li WB
    Drug Res (Stuttg); 2015 Feb; 65(2):74-81. PubMed ID: 24764254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
    Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
    J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.